Lantern Pharma (NASDAQ:LTRN) Announces Earnings Results, Beats Expectations By $0.09 EPS

Lantern Pharma (NASDAQ:LTRN) announced its earnings results on Monday. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.09, FiscalAI reports.

Here are the key takeaways from Lantern Pharma’s conference call:

• Management highlighted a planned FDA Type C meeting for LP-300 (mid-May 2026) proposing protocol amendments to focus on EGFR exon 21 L858R patients, extend treatment cycles to eight, and convert to a single-arm Simon two-stage design to address changing standards of care.
• LP-184 reported encouraging Phase I data (63 patients) with a 48% clinical benefit rate at therapeutic doses, an established RP2D, biomarker-linked activity in DNA damage repair mutations, and planned precision trials in TNBC, NSCLC (KEAP1/STK11), and bladder cancer.
• Wholly-owned subsidiary Starlight/STAR-001 received IND clearance for pediatric CNS trials plus multiple Rare Pediatric Disease and Orphan Drug designations, creating potential for several FDA Priority Review Vouchers as non-dilutive value drivers.
• Lantern is commercializing its RADR/agentic AI product withZeta (AI Center of Excellence in India, 25+ beta partners, multi-tier subscription model) which management says could be a material long-term revenue stream but remains early and unproven.
• Financially, the company had ~$10.1M in cash as of 12/31/25 and expects runway only to roughly late July–mid‑September 2026, stating it will need to raise substantial additional funding in the near term.

Lantern Pharma Stock Performance

LTRN traded up $0.12 during midday trading on Monday, hitting $1.24. The stock had a trading volume of 3,433,002 shares, compared to its average volume of 229,694. Lantern Pharma has a 1 year low of $1.11 and a 1 year high of $5.74. The business has a fifty day moving average of $2.74 and a 200 day moving average of $3.39. The company has a market cap of $13.81 million, a P/E ratio of -0.71 and a beta of 1.53.

Institutional Investors Weigh In On Lantern Pharma

A number of institutional investors have recently made changes to their positions in LTRN. Susquehanna International Group LLP bought a new position in shares of Lantern Pharma during the 3rd quarter valued at $170,000. Vanguard Group Inc. lifted its stake in Lantern Pharma by 5.6% in the third quarter. Vanguard Group Inc. now owns 384,041 shares of the company’s stock worth $1,671,000 after purchasing an additional 20,321 shares during the last quarter. Two Sigma Investments LP purchased a new stake in Lantern Pharma during the third quarter valued at about $70,000. CIBC Private Wealth Group LLC bought a new position in shares of Lantern Pharma during the fourth quarter valued at about $47,000. Finally, XTX Topco Ltd bought a new position in shares of Lantern Pharma during the second quarter valued at about $40,000. Hedge funds and other institutional investors own 28.62% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Lantern Pharma in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $25.00.

About Lantern Pharma

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.